Transient receptor potential (TRP) channels are important targets for discovering novel drugs in a variety of indications, including neuropathic pain or cancer. Together with our partners AcCELLerate and Nanion, we established the pharmacology of recombinant cell lines expressing TRPA1, TRPM8, TRPV1, TRPV3, or TRPV4, in a fluorescent Ca2+-flux assay as well as automated patch-clamp. The cell lines are available as assay-ready frozen cells and can be used directly after thawing for substance screening or profiling of lead candidates.
